데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다
141625-93-6CCCCc1oc2ccc(NS(C)(=O)=O)cc2c1C(=O)c1ccc(OCCCN(CCCC)CCCC)cc1.ClDWKVCQXJYURSIQ-UHFFFAOYSA-NDronedarone Hydrochloride is the hydrochloride salt form of dronedarone, an orally bioavailable benzofuran derivative, with anti-arrhythmic activity. Upon oral administration, and although the exact mechanism of action through which dronedarone exerts its anti-arrhythmic effect has not been fully elucidated, it inhibits multiple voltage-gated ion channels, including sodium, potassium, and calcium ion channels, and restores the normal sinus rhythm and reduces heart rate in atrial fibrillation. It also non-competitively antagonizes adrenergic receptors.
141625-93-6DTXSID30161779CHEMBL1201729FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Pale Yellow Solid
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
This chemical does not meet GHS hazard criteria for 8.3% (1 of 12) of reports.
Warning
H302 (33.3%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P260, P261, P263, P264, P264+P265, P270, P271, P273, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 12 reports by companies from 12 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Drug Induced Liver Injury Rank (DILIrank 2.0)
Dronedarone hydrochloride
vMost-DILI-concern
7
Warnings & precautions
DOI:10.1016/j.drudis.2016.02.015
역사DRONEDARONE HYDROCHLORIDE (brand name: Multaq) is an antiarrhythmic drug developed by Sanofi-Aventis. It was approved by the FDA in July 2009 for the treatment of atrial fibrillation and atrial flutter, reducing the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL). The drug was developed to create a treatment that maintains the therapeutic benefits of amiodarone while reducing associated serious side effects such as pulmonary toxicity and thyroid dysfunction. DRONEDARONE HYDROCHLORIDE is usually administered orally in tablet form. The recommended dose is 400 mg twice daily, one tablet in the morning and one in the evening.
용도Dronedarone Hydrochloride can be used for the treatment of atrial fibrillation and atrial flutter in patients who have suffered cardiac arrhythmias.